GVR Report cover Urinalysis Market Size, Share & Trends Report

Urinalysis Market Size, Share & Trends Analysis Report By Product, By Application (Disease Screening {UTI, Kidney Disease}, Pregnancy & Fertility Testing), By End-use, By Region, And Segment Forecasts, 2022 - 2030

  • Report ID: 978-1-68038-817-6
  • Number of Pages: 150
  • Format: Electronic (PDF)
  • Historical Range: 2018 - 2020
  • Industry: Healthcare

Report Overview

The global urinalysis market size was valued at USD 3,550.2 million in 2021 and is expected to witness a compound annual growth rate (CAGR) of 4.6% from 2022 to 2030. Urinalysis market is witnessing growth due to the factors such as the rising incidence of diseases such as Urinary Tract Infections (UTIs), diabetes, and kidney diseases. The rising usage of automated and advanced According to National Diabetes Statistics Report, 2020, around 34.2 million population aged 18 years and above had diabetes in the U.S. About one-third of diabetes people have kidney-related comorbidities due to high blood sugar and blood pressure. Urinalysis is an informative and noninvasive diagnostic tool that is accessible to clinicians to diagnose kidney disease. Hence, the rising prevalence of kidney diseases is anticipated to increase demand for products that are used in urinalysis, thereby, driving the market growth.

U.S. urinalysis market size, by product, 2020 - 2030 (USD Million)

During the initial phase of the COVID -19 pandemic, the market for urinalysis was moderately impacted due to the low hospitalization rate and declining sales of urine analysis tests. Nationwide lockdowns imposed by governments to control the spread of infection restricted people’s access to diagnostic and hospital services leading to low demand for diagnostics products. However, a resurgence in testing numbers is seen as countries eased restrictions on movement. The growing importance of urinalysis for detecting post-COVID-19 diseases such as acute kidney & tubular injuries is anticipated to drive market growth. According to the Columbia University study (2021), kidney injury marker-1 (KIM-1) and urinary NGAL were two sensitive biomarkers for detecting tubular and kidney injury patients.

Developing countries such as South Korea, Brazil, India, and Mexico are expected to offer potential growth opportunities for key players in the urinalysis market. This can be attributed to the increasing burden of chronic diseases, improved healthcare infrastructure, a large patient base, and increased disposable income. For instance, the healthcare expenditure in India increased from USD 232.73 million in 2020 to USD 507.97 million in 2021.

Furthermore, screening programs are undertaken by governments for the early detection of diseases such as urinary and renal disorders. For instance, around 12,497 students of primary and secondary schools from Pingyang, Cangnan, and Yongjia in Wenzhou, China were screened for urinalysis under school urinary analysis programs. The urine abnormalities were seen in primary school students with a detection rate of 36% and 95% in secondary school students. The rising number of such programs is expected to drive the demand for urinalysis tests.

Increased investment in the development of home-based urine testing kits for disease diagnosis contributes to segment growth. For instance, in November 2021, Vivoo raised funding of USD 6 million for the development of at-home urine tests to provide lifestyle and nutrition guidance. In developing countries, which are price sensitive, preferred inexpensive cost and equally functional analyzers for routine urinalysis tests. Hence, developing low-cost urinalysis tests is expected to fuel market growth.

Product Insights

The consumables segment held the highest market share of 88.0% in 2021. This dominance can be attributed to increasing demand and frequent purchases of reagents and dipsticks by clinical and hospital laboratories. There are many leading providers such as Siemens Healthcare GmBH., Abbott, and Roche provide high-quality consumables for urinalysis testing which is expected to boost the segment growth. For instance, Siemens Healthcare GmBH offers Multistix 10 SG Reagent Strips for diagnosis of UTI, diabetes, and kidney diseases.

Rise in approvals and the launch of new instruments for urinalysis is expected to drive market growth. For instance, in January 2022, Bio-Rad Laboratories, Inc. launched qUAntify Advanced Control instrument to monitor the precision urinalysis test procedure in clinical labs. This instrument increased the effectiveness of the laboratory’s statistical process control and demand for products in the coming years.

Application Insights

The urinary tract infection segment dominated the market and accounted for a revenue share of 25.55% in 2021 due to the rising incidence of UTIs worldwide. According to the National Library of Medicine, around 150 million people suffer from urinary tract infections each year worldwide. The diabetes segment is expected to grow at a lucrative CAGR during the forecast period. Urinalysis is an important screening test to find out about diabetes. According to CDC, in 2022, around 37.3 million populations in the U.S. affected by diabetes. About 28.7 million people are diagnosed and 8.5 million are undiagnosed people. Thus, an increasing number of patients with diabetes acts as a major market driver.

The pregnancy and fertility kits segment is expected to witness a CAGR of 4.6% during the forecast period. The increasing prevalence of infertility and the rise in first pregnancy age is expected to drive the pregnancy and fertility kits market.

End-use Insights

The clinical laboratories segment accounted for a revenue share of around 30.0% in 2021. This can be attributed to easy accessibility to patients and the availability of an advanced product in these laboratories. In the U.S., more than 20,000 clinical laboratories perform clinical tests including urinalysis.

Global urinalysis market share, by end use , 2021 (%)

The home care segment is estimated to witness a significant CAGR during the forecast period due to the increasing launch of home-based UTI test kits. For instance, in August 2020, the TestCard launched of non-invasive at home UTI test kit in UK. The users can access testing results through the accompanying mobile app and share information with a healthcare professional. This test kit is available at a retail pharmacy at a cost of USD 12.06.

Regional Insights

North America dominated the market and accounted for the largest revenue share of 36.6% in 2021. This dominance can be attributed to strategic initiatives undertaken by key players such as licensing agreements to expand business footprint. For instance, in 2020, Sysmex and Siemens Healthcare GmbH signed an exclusive licensing agreement to distribute and service the automated urine analyzer CLINITEK Novus to the hospital & reference laboratories in North America. This agreement has a positive impact on market growth.

Urinalysis Market Trends by Region

In Asia Pacific, the market is estimated to be the fastest-growing region over the forecast period. The presence of domestic urine analyzer manufacturers, such as VSI Electronics Pvt. Ltd and Medical Equipment India; increasing adoption of advanced urine analyses; and the presence of a large patient base with unmet clinical needs are some of the major factors boosting the regional market growth.

Key Companies & Market Share Insights

In December 2021, KDx Diagnostics, Inc., and Lister Hospital launched KDx's URO17 non-invasive urine test for diagnosis of bladder cancer in UK. This launch is expected to strengthen its position in the market. Some of the key players in the global urinalysis market include:

  • Abbott

  • Sysmex Corporation

  • Siemens Healthcare GmbH

  • ACON Laboratories, Inc.

  • ARKRAY Inc.

  • Shenzhen Mindray Bio-Medical Electronics Co., Ltd.

  • F. Hoffmann-La Roche Ltd.

  • Quidel Corporation

  • Bio-Rad Laboratories, Inc.

Urinalysis Market Report Scope

Report Attribute


Market size value in 2022

USD 3,776.9 million

Revenue forecast in 2030

USD 5.4 billion

Growth rate

CAGR of 4.6% from 2022 to 2030

Base year for estimation


Historical data

2018 - 2020

Forecast period

2022 - 2030

Quantitative units

Revenue in USD million and CAGR from 2022 to 2030

Report coverage

Revenue forecast, company ranking, competitive landscape, growth factors, and trends

Segments covered

Product, application, end-use, region

Regional scope

North America; Europe; Asia Pacific; Latin America; MEA

Country scope

U.S.; Canada; Germany; U.K.; France; Italy; Spain; China; Japan; India; Australia; South Korea; Brazil; Mexico; Argentina; South Africa; Saudi Arabia; UAE;

Key companies profiled

Abbott; Sysmex Corporation; ACON Laboratories, Inc.; Bio-Rad Laboratories, Inc.; ARKRAY Inc.; F. Hoffmann-La Roche Ltd.; Shenzhen Mindray Bio-Medical Electronics Co., Ltd.; Siemens Healthcare GmbH; Quidel Corporation

Customization scope

Free report customization (equivalent up to 8 analyst’s working days) with purchase. Addition or alteration to country, regional, and segment scope.

Pricing and purchase options

Avail customized purchase options to meet your exact research needs. Explore purchase options


Global Urinalysis Market Segmentation

This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2018 to 2030. For the purpose of this report, Grand View Research has segmented the global urinalysis market report on the basis of product, application, end-use, and region:

Global Urinalysis Market Segmentation

  • Product Outlook (Revenue, USD Million, 2018 - 2030)

    • Instruments

      • Biochemical Urine Analyzers

        • Automated biochemical analyzers

        • Semi-automated Biochemical Analyzers

      • Automated Urine Sediment Analyzers

        • Microscopic Urine Analyzers

        • Flow-cytometric Urine Analyzers

      • Point-Of-Care Urine Analyzers

    • Consumables

      • Dipsticks

      • Reagents

      • Disposables

      • Pregnancy And Fertility Kits

  • Application Outlook (Revenue, USD Million, 2018 - 2030)

    • Disease Screening

      • UTIs

      • Diabetes

      • Kidney disease

      • Hypertension

      • Liver disease

      • Others

    • Pregnancy And Fertility Testing

  • End-use Outlook (Revenue, USD Million, 2018 - 2030)

    • Hospitals

    • Clinical Laboratories

    • Home Care

    • Research And Academics

    • Others

  • Regional Outlook (Revenue, USD Million, 2018 - 2030)

    • North America

      • U.S.

      • Canada

    • Europe

      • Germany

      • U.K.

      • France

      • Italy

      • Spain

    • Asia Pacific

      • Japan

      • China

      • India

      • Australia

      • South Korea

    • Latin America

      • Brazil

      • Mexico

      • Argentina

    • Middle East and Africa (MEA)

      • South Africa

      • Saudi Arabia

      • UAE

Frequently Asked Questions About This Report

gvr icn


gvr icn

This FREE sample includes market data points, ranging from trend analyses to market estimates & forecasts. See for yourself.

gvr icn


We can customize every report - free of charge - including purchasing stand-alone sections or country-level reports, as well as offer affordable discounts for start-ups & universities.

Contact us now to get our best pricing.

esomar icon

ESOMAR certified & member

D&B icon

Leading SME award by D&B

We are GDPR and CCPA compliant! Your transaction & personal information is safe and secure. For more details, please read our privacy policy.

great place to work icon